Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Plos One|December 7, 2023
Early formative objective structured clinical examinations for students in the pre-clinical years of medical education: A non-randomized controlled prospective pilot studyNaïm Ouldali, Enora Le Roux, Albert Faye, et al.
Journal of Medical Genetics|August 7, 2014
Juvenile myelomonocytic leukaemia and Noonan syndromeMarion Strullu, Aurélie Caye, Julie Lachenaud, et al.
Journal of Cancer|March 14, 2022
Novel Insights into Pediatric Acute Lymphoblastic Leukemia Ophthalmic Relapses from a Nationwide Cohort StudySolenne Le Louet, Véronique Icart, Marion Strullu, et al.
Blood|September 19, 2025
The watch-and-wait approach for patients with juvenile myelomonocytic leukemia: results of the French cohortQuentin Neven, Chloé Arfeuille, Aurélie Caye-Eude, et al.
Cell Reports|June 9, 2023
Distinct subsets of multi-lymphoid progenitors support ontogeny-related changes in human lymphopoiesisSeydou Keita, Samuel Diop, Shalva Lekiashvili, et al.
Haematologica|February 22, 2024
A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie CellulaireDéborah Meyran, Chloé Arfeuille, Sylvie Chevret, et al.
JCI Insight|May 22, 2024
Lentivirus-mediated gene therapy corrects ribosomal biogenesis and shows promise for Diamond Blackfan anemiaYari Giménez, Manuel Palacios, Rebeca Sánchez-Domínguez, et al.
Hemasphere|January 21, 2026
Chronic graft-versus-host disease in long-term survivors of childhood leukemiaPaul Saultier, Gérard Michel, Anne Sirvent, et al.
Haematologica|November 20, 2023
Germline bi-allelic SH2B3/LNK alteration predisposes to a neonatal juvenile myelomonocytic leukemia-like disorderChloé Arfeuille, Yoann Vial, Margaux Cadenet, et al.
BMC Cancer|May 3, 2022
Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocolLinea Natalie Toksvang, Bodil Als-Nielsen, Christopher Bacon, et al.
Pageof 5